We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Partners to Seek Novel Drugs to Treat Fibrotic Diseases

By LabMedica International staff writers
Posted on 27 Jul 2015
A global biopharmaceutical company and an American university hospital-based research institute have agreed to collaborate on the diagnosis and cure of fibrotic diseases.

Fibrotic diseases such as scleroderma, renal fibrosis, and idiopathic pulmonary fibrosis are characterized by the gradual formation of excess fibrous connective tissue in an organ or tissue.

The Medical University of South Carolina (Charleston, USA) and the global pharmaceutical company Bristol-Myers Squibb (New York, NY, USA) announced that they have entered into a translational research collaboration focused on identifying novel medicines to halt or slow the progression of fibrotic disease. The agreement also provides for studies designed to improve the mechanistic understanding of fibrosis and to explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.

“Bristol-Myers Squibb’s collaboration with the Medical University of South Carolina further strengthens and advances our discovery research efforts in fibrotic diseases, a strategic area of focus for the company,” said Dr. Carl Decicco, head of discovery research and development at Bristol-Myers Squibb. “The Medical University of South Carolina brings substantial expertise in translational research and drug discovery related to fibrotic diseases including access to patient derived disease tissue samples that will help us accelerate the application of scientific knowledge to potential new treatment approaches for patients.”

“This is an exciting opportunity with the potential to make a significant impact in fibrotic diseases and in patients’ lives with these debilitating diseases,” said Dr. Karen Lackey, associate professor of pharmacy and executive director for therapeutic discovery development at the Medical University of South Carolina. “Our goal with translational research is to shorten the timeline in getting patients the medications and treatments they need. We have unparalleled expertise in fibrosis research at the Medical University of South Carolina, and this collaboration with a leader like Bristol-Myers Squibb in discovery and development of medications is going to take that foundational work to the next level.”

Related Links:

The Medical University of South Carolina
Bristol-Myers Squibb



Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Thyroxine ELISA
T4 ELISA

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries